Kyverna Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company pioneering the development of fully human chimeric antigen receptor (CAR) T-cell therapies designed specifically for autoimmune diseases. The company's lead autologous candidate, mivocabtagene autoleucel (miv-cel, also known as KYV-101), targets CD19-expressing B cells to achieve deep B-cell depletion and a complete immune system reset. This approach aims to deliver durable, drug-free, and disease-free remission with a single administration. Kyverna is advancing miv-cel across a broad neuroimmunology and rheumatology pipeline, including clinical programs for stiff person syndrome (SPS), generalized myasthenia gravis (gMG), progressive multiple sclerosis (MS), systemic sclerosis (SSc), and lupus nephritis (LN). Additionally, the company is developing KYV-201, an allogeneic CD19 CAR T-cell candidate in partnership with Intellia Therapeutics, utilizing CRISPR/Cas9 gene-editing technology to improve patient access and scale.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing the clinical development of lead asset miv-cel (KYV-101) for high unmet need neuroinflammatory indications, specifically Stiff Person Syndrome (SPS) as the lead indication, followed by generalized Myasthenia Gravis (gMG).
Expected impact: Establishes Kyverna as a first-to-market leader in autoimmune CAR T-cell therapy.
Transitioning from a clinical-stage to a commercial-stage organization by building commercialization infrastructure, scaling operations, and appointing key executives including a new Chief Commercial Officer (Nadia Dac) and Chief Financial Officer (Greg Martini).
Expected impact: Enables rapid market entry, efficient distribution, and clinical adoption of miv-cel upon potential FDA approval.
Advancing KYV-102, a proprietary whole blood, rapid manufacturing process designed to eliminate the apheresis step, improve the patient experience, and broaden patient access to CAR T-cell therapies.
Expected impact: Significantly reduces manufacturing complexity and expands the addressable patient population across broader autoimmune indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides non-dilutive financial flexibility to support late-stage clinical development of miv-cel in SPS and gMG, as well as pre-launch commercialization activities.
Terms: A milestone-based loan facility of up to $150 million, with an initial draw of $25 million closed in November 2025.